Curated News
By: NewsRamp Editorial Staff
May 29, 2026

Regentis Biomaterials' GelrinC® Poised to Transform Knee Cartilage Repair

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Regentis Biomaterials' GelrinC hydrogel offers a 10-minute knee repair, targeting a $3B U.S. market with no approved off-the-shelf competitor.
  • GelrinC is a cell-free hydrogel implant that degrades in the knee, allowing natural cartilage regeneration in a controlled, synchronous process.
  • GelrinC provides a simpler, single-step knee cartilage repair that improves pain and regenerates tissue, potentially enhancing quality of life for many.
  • GelrinC achieved 100% greater pain improvement than microfracture, with MRI-confirmed near-native cartilage regeneration lasting years.

Impact - Why it Matters

This news matters because it introduces a potential paradigm shift in knee cartilage repair. GelrinC® could offer a simpler, faster, and more effective alternative to current treatments like microfracture, which often yields mixed results, and complex cell-based therapies that require multiple surgeries. For the 470,000 Americans who suffer knee cartilage damage each year, a one-step, off-the-shelf solution could mean reduced pain, faster recovery, and better long-term outcomes. The product's progress through a pivotal U.S. trial and its CE Mark approval in Europe signal a significant step toward addressing a critical unmet medical need.

Summary

Regentis Biomaterials Ltd. is revolutionizing knee cartilage repair with GelrinC®, a cell-free hydrogel implant that offers a single-step, approximately 10-minute procedure. This innovative treatment targets an estimated $3 billion U.S. market, encompassing roughly 470,000 annual knee cartilage repair cases where no approved off-the-shelf regenerative solution currently exists. Clinical data show approximately 100% greater pain improvement versus microfracture, along with MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Their Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This product aims to address a significant unmet need, as no off-the-shelf treatment is currently available for the approximately 470,000 cases of cartilage knee repair annually in the U.S.

For investors, the latest news and updates relating to RGNT are available in the company's newsroom. BioMedWire (BMW), a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, is powered by IBN and provides a range of services including press release enhancement and social media distribution. BMW is uniquely positioned to serve private and public companies seeking to reach a wide audience of investors, influencers, and consumers. The company's dynamic brand portfolio and syndication to 5,000+ outlets ensure maximum impact for its clients.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials' GelrinC® Poised to Transform Knee Cartilage Repair

blockchain registration record for this content.